Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon?

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: new advances and challenges. World J. Hepatol. 7(5), 787–798 (2015).
  MedlineGoogle Scholar
• 2 Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin. Oncol. 39(4), 461–472 (2012).
  Medline CASGoogle Scholar
• 3 Scudellari M. Drug development: try and try again. Nature 516(7529), S4–S6 (2014). • Describes the present challenges of drug development for hepatocellular carcinoma. Why sorafenib is effective and why new drugs tend to fail.
  Medline CASGoogle Scholar
• 4 Berliner L, Lemke HU. An Information Technology Framework for Predictive, Preventive and Personalised Medicine: A Use-Case with Hepatocellular Carcinoma. Springer International Publishing, Cham, Switzerland (2015). •• An integrative view in the management of hepatocellular carcinoma: how to implement a model-guided therapy for innovative strategies and personalized treatments, current treatments, challenges and future perspective.
  Google Scholar
• 5 Akyol G, Yilmaz G. Stem cell expression profile in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Stem Cell Transl. Investig. 1, e232 (2014).
  Google Scholar
• 6 Van Thiel DH, Ramadori G. Non-viral causes of hepatocellular carcinoma. J. Gastrointest. Cancer 42(4), 191–194 (2011).
  MedlineGoogle Scholar
• 7 O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes. Rev. 16(1), 1–12 (2015).
  MedlineGoogle Scholar
• 8 Cebioglu M, Schild H, Golubnitschaja O. Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J. 1(1), 130–137 (2010).
  MedlineGoogle Scholar
• 9 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA. Cancer J. Clin. 65(2), 87–108 (2015).
  MedlineGoogle Scholar
• 10 Park JW, Chen M, Colombo M et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 35(9), 2155–2166 (2015).
  MedlineGoogle Scholar
• 11 Mohanty S, Verma S, Dosik D, Hazin H, Berliner L. Hepatocellular carcinoma and patient assessment. In: An Information Technology Framework for Predictive, Preventive and Personalised Medicine. Berliner L, Lemke HU (Eds.). Springer International Publishing, Cham, Switzerland, 21–32 (2015).
  Google Scholar
• 12 Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Annu. Surg. 261(5), 947–955 (2015).
  MedlineGoogle Scholar
• 13 Thein HH, Isaranuwatchai W, Campitelli MA et al. Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology 58(4), 1375–1384 (2013).
  MedlineGoogle Scholar
• 14 Llovet JM, Ducreux M, Lencioni R et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908–943 (2012).
  MedlineGoogle Scholar
• 15 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J. Hepatol. 7(3), 406–424 (2015).
  MedlineGoogle Scholar
• 16 Berliner L, Lemke HU, vanSonnenberg E et al. Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine. EPMA J. 5(1), 16 (2014).
  MedlineGoogle Scholar
• 17 Yamakado K, Hirota S. Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. World J. Gastroenterol. 21(37), 10604–10608 (2015).
  Medline CASGoogle Scholar
• 18 Sinn DH, Cho J-Y, Gwak G-Y et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS ONE 10(4), e0124434 (2015).
  MedlineGoogle Scholar
• 19 Yau T, Tang VYF, Yao T-J, Fan S-T, Lo C-M, Poon RTP. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146(7), 1691.e3–1700.e3 (2014).
  MedlineGoogle Scholar
• 20 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB 7(1), 35–41 (2005).
  Google Scholar
• 21 Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann. Surg. 245(6), 909–922 (2007).
  MedlineGoogle Scholar
• 22 Bester L, Meteling B, Boshell D, Chua TC, Morris DL. Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature. J. Med. Imaging Radiat. Oncol. 58(3), 341–352 (2014).
  MedlineGoogle Scholar
• 23 Xie F, Zang J, Guo X et al. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J. Cancer Res. Clin. Oncol. 138(3), 455–462 (2012).
  Medline CASGoogle Scholar
• 24 Gramenzi A, Golfieri R, Mosconi C et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 35(3), 1036–1047 (2015).
  Medline CASGoogle Scholar
• 25 Yu SJ, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J. Hepatol. 7(11), 1553–1561 (2015).
  MedlineGoogle Scholar
• 26 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: role and perspectives. World J. Hepatol. 7(5), 738–752 (2015).
  MedlineGoogle Scholar
• 27 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
  Medline CASGoogle Scholar
• 28 Gnoni A, Santini D, Scartozzi M et al. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin. Ther. Targets 19(12), 1623–1635 (2015).
  Medline CASGoogle Scholar
• 29 Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J. Hepatol. 5(7), 345–352 (2013).
  MedlineGoogle Scholar
• 30 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 11(6), 604–611 (2013).
  MedlineGoogle Scholar
• 31 Wong CC, Tse AP, Huang YP et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology 60(5), 1645–1658 (2014).
  Medline CASGoogle Scholar
• 32 Vanharanta S. A hypoxic ticket to the bone metastatic niche. Breast Cancer Res. 17, 122 (2015).
  MedlineGoogle Scholar
• 33 Cox TR, Rumney RMH, Schoof EM et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522(7554), 106–110 (2015).
  Medline CASGoogle Scholar
• 34 Arzumanyan A, Reis HMGPV, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer 13(2), 123–135 (2013).
  Medline CASGoogle Scholar
• 35 Lafaro KJ, Demirjian AN, Pawlik TM. Hepatocellular Cancer, Cholangiocarcinoma, and Metastatic Tumors of the Liver. Wagman L (Ed.). Elsevier Health Sciences, Philadelphia, PA, USA, 1–19 (2014).
  Google Scholar
• 36 Welzel TM, Graubard BI, Quraishi S et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am. J. Gastroenterol. 108(8), 1314–1321 (2013).
  MedlineGoogle Scholar
• 37 Donato F, Tagger A, Chiesa R et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case–control study in Italy. Brescia HCC Study. Hepatol. Baltim. Md. 26(3), 579–584 (1997).
  Medline CASGoogle Scholar
• 38 Hassan MM, Hwang LY, Hatten CJ et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36(5), 1206–1213 (2002).
  Medline CASGoogle Scholar
• 39 Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127(5), 1372–1380 (2004).
  MedlineGoogle Scholar
• 40 McGlynn KA, Quraishi S, Welzel TM, Davila JA, El-Serag HB, Graubard BI. Attributable risks for hepatocellular carcinoma in the United States. Cancer Res. 70(Suppl. 8), Abstract 1816 (2010).
  Google Scholar
• 41 Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr. Med. Res. Opin. 26(9), 2183–2191 (2010).
  Medline CASGoogle Scholar
• 42 Ertle J, Dechêne A, Sowa J-P et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 128(10), 2436–2443 (2011).
  Medline CASGoogle Scholar
• 43 Trichopoulos D, Bamia C, Lagiou P et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case–control study. J. Natl Cancer Inst. 103(22), 1686–1695 (2011).
  MedlineGoogle Scholar
• 44 Anthony PP. Hepatocellular carcinoma: an overview. Histopathology 39(2), 109–118 (2001).
  Medline CASGoogle Scholar
• 45 Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118(12), 3030–3044 (2006).
  Medline CASGoogle Scholar
• 46 Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45(4), 529–538 (2006).
  MedlineGoogle Scholar
• 47 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362(9399), 1907–1917 (2003).
  MedlineGoogle Scholar
• 48 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J. Clin. Gastroenterol. 47(Suppl.), S2–S6 (2013).
  MedlineGoogle Scholar
• 49 Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ. Health Perspect. 118(6), 818–824 (2010).
  Medline CASGoogle Scholar
• 50 Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-medicare database. Hepatology 54(2), 463–471 (2011).
  MedlineGoogle Scholar
• 51 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36(6), 1349–1354 (2002).
  MedlineGoogle Scholar
• 52 Dyson J, Jaques B, Chattopadyhay D et al. Hepatocellular cancer: the impact of obesity, Type 2 diabetes and a multidisciplinary team. J. Hepatol. 60(1), 110–117 (2014).
  MedlineGoogle Scholar
• 53 Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54(4), 533–539 (2005).
  Medline CASGoogle Scholar
• 54 Connolly GC, Safadjou S, Kashyap R, Orloff M, Khorana AA, Hezel AF. The impact of diabetes mellitus on survival in hepatocellular carcinoma. J. Clin. Oncol. 28(Suppl. 15), e14596 (2010).
  Google Scholar
• 55 Hassan MM, Abdel-Wahab R, Kaseb A et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology 149(1), 119–129 (2015).
  MedlineGoogle Scholar
• 56 Schütte K, Tippelt B, Schulz C et al. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin. Nutr. 34(6), 1122–1127 (2015).
  MedlineGoogle Scholar
• 57 Wang K. Molecular mechanisms of hepatic apoptosis. Cell Death Dis. 5, e996 (2014).
  Medline CASGoogle Scholar
• 58 Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144(3), 512–527 (2013).
  MedlineGoogle Scholar
• 59 Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J. Hepatol. 61(4), 912–924 (2014).
  Medline CASGoogle Scholar
• 60 El-Serag HB. Hepatocellular carcinoma. N. Engl. J. Med. 365(12), 1118–1127 (2011).
  Medline CASGoogle Scholar
• 61 Sung W-K, Zheng H, Li S et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44(7), 765–769 (2012).
  Medline CASGoogle Scholar
• 62 Ali A, Abdel-Hafiz H, Suhail M et al. Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World J. Gastroenterol. 20(30), 10238–10248 (2014).
  Medline CASGoogle Scholar
• 63 Oikawa T, Ojima H, Yamasaki S, Takayama T, Hirohashi S, Sakamoto M. Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 980 resected nodules. J. Hepatol. 42(2), 225–229 (2005).
  MedlineGoogle Scholar
• 64 Hazin H, Dosik D. Personalized chemotherapy for hepatocellular carcinoma. In: An Information Technology Framework for Predictive, Preventive and Personalised Medicine. Berliner L, Lemke HU (Eds.). Springer International Publishing, Cham, Switzerland, 53–60 (2015)
  Google Scholar
• 65 Ferrari C. HBV and the immune response. Liver Int. 35(s1), 121–128 (2015).
  Medline CASGoogle Scholar
• 66 Barjon C, Dahlqvist G, Calmus Y, Conti F. Role of regulatory T-cells during hepatitis C infection: From the acute phase to post-transplantation recurrence. Dig. Liver Dis. 47(11), 913–917 (2015).
  Medline CASGoogle Scholar
• 67 Bhattacharya A, Hegazy AN, Deigendesch N et al. Superoxide dismutase 1 protects hepatocytes from type I interferon-driven oxidative damage. Immunity 43(5), 974–986 (2015).
  Medline CASGoogle Scholar
• 68 Lu T, Seto WK, Zhu RX, Lai CL, Yuen MF. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J. Gastroenterol. 19(47), 8887–8894 (2013).
  Medline CASGoogle Scholar
• 69 Shiffman ML, Benhamou Y. Cure of HCV related liver disease. Liver Int. 35(Suppl. 1), 71–77 (2015).
  MedlineGoogle Scholar
• 70 Abdel-Razek W, Waked I. Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int. 35(Suppl. 1), 27–34 (2015).
  Medline CASGoogle Scholar
• 71 Walker CM, Grakoui A. Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? Curr. Opin. Immunol. 35, 137–143 (2015).
  Medline CASGoogle Scholar
• 72 Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J. Obes. 2012, 483135 (2012).
  MedlineGoogle Scholar
• 73 Golubnitschaja O. Gender specific complications in female diabetic patients: an integrative view. EPMA J. 5(Suppl. 1), A78 (2014).
  Google Scholar
• 74 Kawada N, Imanaka K, Kawaguchi T et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J. Gastroenterol. 44(12), 1190–1194 (2009).
  MedlineGoogle Scholar
• 75 Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA J. 5(1), 21 (2014). •• Detailed description of the importance of predictive, preventive, personalized and participatory medicine in management of liver diseases: preventable risk factors and lifestyle impacts.
  MedlineGoogle Scholar
• 76 Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol. Rev. 90(3), 1165–1194 (2010).
  Medline CASGoogle Scholar
• 77 Fujiwara N, Nakagawa H, Kudo Y et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J. Hepatol. 63(1), 131–140 (2015).
  Medline CASGoogle Scholar
• 78 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 21(13), 3777–3785 (2015).
  Medline CASGoogle Scholar
• 79 Lam V, Su J, Koprowski S et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 26(4), 1727–1735 (2012).
  Medline CASGoogle Scholar
• 80 Bubnov RV, Spivak MY, Lazarenko LM, Bomba A, Boyko NV. Probiotics and immunity: provisional role for personalized diets and disease prevention. EPMA J. 6(1), 14 (2015).
  MedlineGoogle Scholar
• 81 Yoshimoto S, Loo TM, Atarashi K et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499(7456), 97–101 (2013).
  Medline CASGoogle Scholar
• 82 Son G, Kremer M, Hines IN. Contribution of gut bacteria to liver pathobiology. Gastroenterol. Res. Pract. 2010, 453563 (2010).
  MedlineGoogle Scholar
• 83 Miele L, Valenza V, La Torre G et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49(6), 1877–1887 (2009).
  Medline CASGoogle Scholar
• 84 Zhang H-L, Yu L-X, Yang W et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J. Hepatol. 57(4), 803–812 (2012).
  MedlineGoogle Scholar
• 85 Bala S, Marcos M, Gattu A, Catalano D, Szabo G. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS ONE 9(5), e96864 (2014).
  MedlineGoogle Scholar
• 86 Speliotes EK, Yerges-Armstrong LM, Wu J et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7(3), e1001324 (2011).
  Medline CASGoogle Scholar
• 87 Trepo E, Nahon P, Bontempi G et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 59(6), 2170–2177 (2014).
  Medline CASGoogle Scholar
• 88 Gorden A, Yang R, Yerges-Armstrong LM et al. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Hum. Hered. 75(1), 34–43 (2013).
  Medline CASGoogle Scholar
• 89 Bang KB, Cho YK. Comorbidities and metabolic derangement of NAFLD. J. Lifestyle Med. 5(1), 7–13 (2015).
  MedlineGoogle Scholar
• 90 Ampuero J, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev. Esp. Enfermedades Dig. 107(1), 10–16 (2015).
  MedlineGoogle Scholar
• 91 Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J. Gastroenterol. 20(37), 13306–13324 (2014).
  MedlineGoogle Scholar
• 92 Jepsen P. Comorbidity in cirrhosis. World J. Gastroenterol. 20(23), 7223–7230 (2014).
  MedlineGoogle Scholar
• 93 Klein J, Dawson LA, Tran TH et al. Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy. Curr. Oncol. Tor. Ont. 21(2), e340–e344 (2014).
  Medline CASGoogle Scholar
• 94 Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J. Gastroenterol. 18(24), 3035–3049 (2012).
  Medline CASGoogle Scholar
• 95 Watanabe M, Shibuya A, Minamino T et al. Benefits and problems of transarterial therapy in patients with hepatocellular carcinoma and chronic kidney disease. J. Vasc. Interv. Radiol. 25(12), 1947–1955 (2014).
  MedlineGoogle Scholar
• 96 Wiginton CD, Kelly B, Oto A et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. Am. J. Roentgenol. 190(4), 1060–1068 (2008).
  MedlineGoogle Scholar
• 97 Grech G, Zhan X, Yoo BC et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 6(1), 9 (2015). •• Highlights innovative predictive and preventive strategies in cancer management and provides recommendations for personalized patient care and perspectives for improved medical services.
  MedlineGoogle Scholar
• 98 Hu R, Wang X, Zhan X. Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J. 4(1), 2 (2013).
  MedlineGoogle Scholar
• 99 Golubnitschaja O, Cebioglu M, Yeghiazaryan K, Pieper C, Schild HH. “Molecular signature” in blood of liver cancer diagnosed patients as a criterion for optimal therapy modalities. EPMA J. 5(Suppl. 1), A38 (2014). •• Highlights benefits of minimal-invasive diagnostic approaches and specifically of ‘molecular signature’ in patient stratification for the personalization of treatment strategies in liver cancer.
  Google Scholar
• 100 Trovato GM. Behavior, nutrition and lifestyle in a comprehensive health and disease paradigm: skills and knowledge for a predictive, preventive and personalized medicine. EPMA J. 3(1), 8 (2012).
  MedlineGoogle Scholar
• 101 Yu SY, Zhu YJ, Li WG. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol. Trace Elem. Res. 56(1), 117–124 (1997).
  Medline CASGoogle Scholar
• 102 Björnstedt M, Fernandes AP. Selenium in the prevention of human cancers. EPMA J. 1(3), 389–395 (2010).
  MedlineGoogle Scholar
• 103 Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid. Redox Signal. 9(7), 775–806 (2007).
  Medline CASGoogle Scholar
• 104 Carreras O, Ojeda M, Nogales F. Selenium dietary supplementation and oxidative balance in alcoholism. In: Molecular Aspects of Alcohol and Nutrition. Patel V (Ed.). Academic Press, San Diego, CA, USA, 133–142 (2016).
  Google Scholar
• 105 Assy N, Nassar F, Nasser G, Grosovski M. Olive oil consumption and non-alcoholic fatty liver disease. World J. Gastroenterol. 15(15), 1809–1815 (2009).
  Medline CASGoogle Scholar
• 106 Yeh C-B, Hsieh M-J, Lin C-W et al. The antimetastatic effects of resveratrol on hepatocellular carcinoma through the downregulation of a metastasis-associated protease by SP-1 modulation. PLoS ONE 8(2), e56661 (2013).
  Medline CASGoogle Scholar
• 107 Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat. Rev. 36(1), 43–53 (2010).
  Medline CASGoogle Scholar
• 108 Gómez-Zorita S, Fernández-Quintela A, Macarulla MT et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br. J. Nutr. 107(2), 202–210 (2012).
  Medline CASGoogle Scholar
• 109 Abraham J-A, Golubnitschaja O. Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma. EPMA J. 7(Suppl. 1), A1 (2016). •• Provides information for an optimal setup of predictive and prognostic biomarker panel, which may sufficiently improve screening programs and individual outcomes in hepatocellular carcinoma.
  MedlineGoogle Scholar
• 110 Lee JH, Kim K-H, Park J-W et al. Low-mass-ion discriminant equation: a new concept for colorectal cancer screening. Int. J. Cancer 134(8), 1844–1853 (2014).
  Medline CASGoogle Scholar
• 111 Chen T, Xie G, Wang X et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol. Cell. Proteomics 10(7), M110.004945 (2011).
  Google Scholar
• 112 Pesta M, Kulda V, Narsanska A, Fichtl J, Topolcan O. May CTC technologies promote better cancer management? EPMA J. 6(1), 1 (2015). •• Describes advantages of predictive and prognostic approaches by detection and characterization of circulating tumor cells as an innovative, minimally invasive diagnostic tool.
  MedlineGoogle Scholar
• 113 Kelley RK, Magbanua MJM, Butler TM et al. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer 15, 206 (2015).
  MedlineGoogle Scholar
• 114 Dekervel J, van Pelt J, Verslype C. Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding? Curr. Opin. Oncol. 25(4), 409–416 (2013).
  Medline CASGoogle Scholar
• 115 Savic LJ, Chapiro J, Duwe G, Geschwind J-F. Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond? Hepatic Oncol. 3(1), 19–28 (2016).
  Google Scholar
• 116 Delire B, Stärkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur. J. Clin. Invest. 45(6), 609–623 (2015).
  Medline CASGoogle Scholar
• 117 Waidmann O, Trojan J. Novel drugs in clinical development for hepatocellular carcinoma. Expert Opin. Investig. Drugs 24(8), 1075–1082 (2015).
  Medline CASGoogle Scholar
• 118 Bubnov RV, Melnyk IM. Hepatic oncology diagnosis based on imaging fractal analysis: preliminary results. EPMA J. 5(Suppl. 1), A43 (2014). •• Describes an innovative strategy to improve the diagnostic output by personalized 3D imaging that reduces subjectivity and facilitates targeted treatments.
  Google Scholar
• 119 Lemke HU, Golubnitschaja O. Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within “Horizon 2020.” EPMA J. 5(1), 8 (2014).
  MedlineGoogle Scholar
• 120 The European Association for Predictive, Preventive and Personalised Medicine (EPMA). http://epmanet.eu/
  Google Scholar
• 121 Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: White Paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 3(1), 14 (2012).
  MedlineGoogle Scholar
• 122 Shi M, Chen M-S, Sekar K, Tan C-K, Ooi LL, Hui KM. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur. J. Cancer 50(5), 928–936 (2014).
  Medline CASGoogle Scholar
• 123 Dai M, Chen X, Liu X, Peng Z, Meng J, Dai S. Diagnostic value of the combination of Golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: a meta-analysis. PLoS ONE 10(10), e0140067 (2015).
  MedlineGoogle Scholar
• 124 Golubnitschaja O, Watson ID, Topic E, Sandberg S, Ferrari M, Costigliola V. Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA J. 4(1), 12 (2013).
  MedlineGoogle Scholar
• 125 WHO/Europe | Vienna conference on nutrition and noncommunicable diseases – Vienna Declaration on Nutrition and Noncommunicable Diseases in the Context of Health 2020. www.euro.who.int/en/health-topics/disease-prevention/nutrition/publications/2013/vienna-declaration-on-nutrition-and-noncommunicable-diseases-in-the-context-of-health-2020
  Google Scholar
• 126 Abraham J-A, Yeghiazaryan K, Golubnitschaja O. Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalisation. Pers. Med. 13(4), 347–360 (2016).
  CASGoogle Scholar